Here we present the safety, tolerability and anti-tumor activity of a first-in-child New Approaches to Neuroblastoma Therapy (NANT) Consortium phase 1 study (NANT2015-02) of lorlatinib in children, adolescents and adults with ALK-driven refractory or relapsed neuroblastoma. This evidence concerns the gene ALK and neoplasm.